Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbenicillin Indanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | RECQL | P46063 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | CCKBR | P32239 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbenicillin Indanyl SCHEMBL33855 | 1.00 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL33857 | 1.00 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL29592774 | 1.00 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL11309244 | 1.00 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL10741454 | 1.00 | KDM4E (0.57) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL22818119 | 0.99 | KDM4E (0.56) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL954017 | 0.99 | KDM4E (0.56) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL11311104 | 0.99 | KDM4E (0.56) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL15668574 | 0.98 | PTGS1 (0.56) | KDM4ERECQLTDP1MEN1KMT2A | |
| Carbenicillin Indanyl SCHEMBL1736359 | 0.97 | PTGS1 (0.55) | KDM4ERECQLTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4304717-A | Process for the preparation of reactive penicillanic acid and cephalosporanic acid derivatives | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1981-12-08 | — | — | US | claimed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | KDM4E 2934/4885RECQL 756/4885TDP1 3879/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | KDM4E 2315/4885RECQL 1092/4885TDP1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.